论文信息 - The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

The design and profile of a series of adamantyl-containing long acting beta(2)-adrenoreceptor agonists are described. An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacology profile when assessed using a guinea pig trachea tissue model. A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clinical trials.

[1] G. Anderson. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[2] A. Tattersfield,et al. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. , 1999, The European respiratory journal.

[3] J C Yernault,et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[4] R. A. Coleman,et al. Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterol , 1993, British journal of pharmacology.

[5] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[6] B. Waldeck. Beta-adrenoceptor agonists and asthma--100 years of development. , 2002, European journal of pharmacology.

[7] R. Austin,et al. QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.

[8] J. Lötvall,et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[9] Alan Daniel Brown,et al. The discovery of long acting β2-adrenoreceptor agonists , 2007 .